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Neoadjuvant chemotherapy has been established as the standard of care for HER2-positive breast 
cancer since it allows cancer down-staging, up to pathological complete response. The standard of 
care in the neoadjuvant setting for HER2-positive breast cancer is a combination of highly cytotoxic 
drugs such as anthracyclines and the anti-HER2 monoclonal antibody. Despite this cocktail allows a 
pathological complete response in up to 50%, their co-administration is strongly limited by intrinsic 
cardiotoxicity. Therefore, only a sequential administration of anthracyclines and the anti-HER2 
treatment is allowed. Here, we propose the anthracycline formulation in H-Ferritin nanocages 
as promising candidate to solve this unmet clinical need, thanks to its capability to increase 
anthracyclines efficacy while reducing their cardiotoxicity. Treating a murine model of HER2-positive 
breast cancer with co-administration of Trastuzumab and H-Ferritin anthracycline nanoformulation, 
we demonstrate an improved tumor penetration of drugs, leading to increased anticancer efficacy and 
reduced of cardiotoxicity.
In recent years, neoadjuvant chemotherapy (NACT) has been established as the standard of care for HER2-
positive breast cancer (BC)1. Indeed, treating patients by NACT before surgery allows cancer down-staging, up 
to pathological complete response (pCR) both in primary tumor and in the axilla. The main advantage is to make 
operable inoperable lesions, or to convert the indication for total mastectomy and complete axillary dissection 
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into more conservative surgical  approaches2. Moreover, pCR is highly predictive of favourable long-term onco-
logic  outcomes3. Thus, obtaining pCR is currently the main goal of NACT. The mainstay of NACT for HER2-
positive BC is the anti-HER2 monoclonal antibody trastuzumab (TZ), since its introduction in clinical practice 
has profoundly changed the natural history of this aggressive subtype of  BC4,5. However, TZ as a single therapy 
has a scarce antitumor activity and needs to be associated with a highly cytotoxic drug such as an  anthracycline6. 
Combination of anthracyclines with TZ has dramatically increased the pCR rate up to 50%, thus establishing 
itself as the standard NACT regimen in HER2-positive  BC2. However, the great efficacy of these two drugs is 
strongly limited by their intrinsic cardiotoxicity, both related with acute adverse effects and chronic develop-
ment of left ventricular systolic  dysfunction7. Therefore, administration of anthracyclines and TZ is sequential 
in current clinical practice. But this higher efficacy is counterbalanced by overwhelming cardiotoxicity, leading 
to heart failure in up to 27% of  patients8. Administering NACT with concurrent use of anthracyclines and TZ 
is therefore a clinical unmet need. Nanomedicine holds a great potential in responding to currently unsolved 
issues, providing smart drug delivery systems which are specifically targeted toward cancer cells, thus limiting 
off-target toxicity. The novel anthracycline formulation exploiting H-Ferritin (HFn)-nanocages has proven to 
be the optimal candidate for clinical translation in BC therapy, thanks to its capability to increase doxorubicin 
(DOX) anticancer effect while reducing its  cardiotoxicity9. The aim of the present study was to assess the efficacy 
and the cardiotoxicity of a combined NACT with nanoformulated DOX (HFn-DOX) and TZ in a murine model 
of HER2-positive BC.
Results
The combination of HFn-DOX with TZ displays increased antitumor potential. To assess the 
feasibility of the combined administration of the anthracycline Doxorubicin and the anti-HER2 targeted therapy 
with TZ, we exploited the “cardiosafe” formulation of DOX named HFn-DOX. BALB/c female mice bearing 
D2F2/E2 tumor, which is a murine BC expressing human HER2 receptor and hence responsive to TZ, were 
randomly divided into six experimental groups at day 7 and treated with placebo, HFn-DOX or free DOX, TZ 
or with the combination of HFn-DOX + TZ or DOX + TZ. The treatment was repeated twice a week for 2 weeks 
and half. Growth profiles reported in Fig. 1A evidences that both the combination of and the single treatments 
with nanoformulated DOX (i.e. TZ and HFn-DOX) were effective in reducing tumor growth in comparison 
to the group treated with placebo. Despite this, in the groups treated with TZ or HFn-DOX as single agent, we 
could only slow down tumor growth, while in the group treated with the combination of TZ and HFn-DOX we 
could notice tumor regression. DOX displays lower efficacy that nanoformulated HFn-DOX, as expected from 
previous evidences in Triple-Negative Breast Cancer murine  model9. Therefore, the growth profile of this group 
is quite similar to placebo. Moreover, also in group treated with the combination of DOX and TZ, the efficacy 
in comparison to placebo seems to be similar to that observed in groups treated with TZ or with HFn-DOX as 
single agents. These observations were confirmed by tumor size measurements performed after tumor dissec-
tion (Fig. 1B). Tumor size reduction is statistically significant in comparison to placebo only in groups treated 
with TZ as single agent or in combination with HFn-DOX, despite tumor sizes observed in mice treated with 
TZ alone were larger than those measured in the group treated with the combination of HFn-DOX and TZ, 
suggesting an additive effect due to the combination of these drugs. To characterize in depth the anticancer 
effects of TZ and HFn-DOX combination, we evaluated the capability to induce apoptosis by cleaved caspase 
3 staining (Fig. 1C), tunel assay (Fig. 1D) and Granzyme B release upon Antibody Dependent Cell-mediated 
Cytotoxicity (ADCC), (Fig. 1E, F). As expected, the labelling with cleaved caspase 3 antibody confirms results 
of tumor size, since the red fluorescence signal of cleaved caspase 3 is clearly detectable only in samples from 
HFn-DOX + TZ group. An increase in the number of apoptotic nuclei has been detected in tumor samples from 
drug-treated mice in comparison to ones from mice of the placebo group. Single treatment with HFn-DOX was 
more effective than DOX in induce nuclei fragmentation, both as single treatment, both in combination with 
TZ. Although differences between the group treated with TZ alone and HFn-DOX or DOX alone have not been 
evidenced, mice treated with their combination displayed a higher amount of apoptosis in comparison to ones 
treated with a single drug, suggesting a synergic effect of TZ-anthracycline combination. Since the engagement 
of Fc gamma receptor-expressing leukocytes—especially natural killer cells (NK)—with TZ has been shown to 
potently induce  ADCC10, we evaluated by western blot the presence of Granzyme B in tumor lysates as readout 
(Fig. 1E, F and Supplementary Fig. 5). As expected, the amount of this cytotoxic protein was much more abun-
dant in groups treated with TZ. The higher amount of Granzyme B was actually due to cellular activation and not 
to an enhanced intratumor leukocyte recruitment, given that the percentage of NK, T cells and NK-T cells did 
not vary among cured TZ and HFn-DOX + TZ groups (Supplementary Fig. 1). Otherwise in DOX + TZ group, 
the increase in Granzyme B is coupled with an increase in NK population suggesting an enhancement in intra-
tumor leukocyte engagement. Importantly, we found that ADCC occurred in similar extent in samples from 
mice treated with TZ as single agent or in combination with HFn-DOX or DOX, indicating that the presence of 
Doxorubicin did not interfere with the effector functions of tumor-infiltrating leukocytes.
HFn-DOX protects against TZ-induced mitochondrial cardiotoxicity. Once documented the 
improved anticancer activity of the TZ and HFn-DOX combination in comparison to the single treatments, we 
assessed their toxicity in off-target organs with particular regard to the heart. Indeed, cardiotoxicity represents 
the main side-effect associated with DOX administration and it is also a drawback often associated to TZ treat-
ment, since HER2 overexpression plays a pivotal role also in cardiomyocytes growth, survival and inhibition of 
 apoptosis11,12. Both neoadjuvant and adjuvant clinical trials have challenged the notion that TZ should not be 
administered with  DOX13, despite pre-clinical and clinical studies demonstrated that their coadministration 
results in the significant enhancement of antitumor  efficacy14–16. To verify whether HFn-DOX could make feasi-
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Figure 1.  In vivo efficacy of the combined treatment with TZ and HFn-DOX. (A) Tumor progression in D2F2/
E2 tumor bearing BALB/c mice (n = 15/group) treated with placebo, HFn-DOX or DOX (1 mg/Kg of DOX, 
i.v.), TZ (5 mg/Kg, i. p.) and with the combination of them (HFn-DOX + TZ or DOX + TZ). (B) Tumor volume 
measured at day 24. Plot reported individual values ± s.e. Statistical significance vs placebo *P < 0.05; ***P < 0.005. 
(C) Immunofluorescence with cleaved caspase 3 antibody (red) on histological slides of OCT embedded tumors 
excised at day 24. Magnification 40 ×. Nuclei have been labelled with DAPI (blue) and cellular membranes with 
Alexa Fluor488-Wheat Germ Agglutinin (green). Scale bar = 30 µm. (D) Quantification of apoptosis in tumor 
tissue upon treatment (n = 8/group). Reported values are the mean of apoptotic cells number/field/sample ± s.e. 
The count was performed on 10 fields/sample. Statistical significance vs. placebo ***P < 0.0005; ****P < 0.0001; 
#P < 0.05, ##P < 0.01, ###P < 0.005. (E) Quantification of western blot analysis performed on tumors excised at the end 
of treatment to quantify granzyme release. Granzyme was normalized on tubulin using ImageJ Software. Reported 
values are the mean of 3 samples ± s.e. (F) Representative results of western blots performed to quantify Granzyme, 
constituted by cropped western blots revealed with anti-Granzyme B antibody and anti-α tubulin, respectively.
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ble the therapeutic combination of TZ and DOX in the management of  HER2+ BC, we analyzed heart tissue of 
mice treated with placebo, TZ, DOX, HFn-DOX, and with the combination of HFn-DOX + TZ and DOX + TZ 
in order to find typical morphological mitochondrial alteration due to cardiotoxicity. Detailed ultrastructural 
analysis of cardiac tissue revealed alterations in mitochondria homeostasis in groups treated with DOX both 
as single agent or as combination with TZ, while in groups treated with TZ, HFn-DOX and HFn-DOX + TZ 
the amount of mitochondria is the same to that observed in placebo group. Besides, an increase in mitochon-
dria area coupled with cristae depletion has been detected in cured arms (Fig. 2B,C). More severe clinical pic-
ture were detected in groups treated with TZ or DOX as single agents, suggesting their crucial role in induce 
cardiotoxicity. The absence of massive alterations in cardiac mitochondria from mice treated with HFn-DOX 
alone was not surprising, since we have already demonstrated in a previous work that the nanoformulation in 
HFn prevents DOX cardiotoxicity in mice bearing 4T1  tumors9. However, it is surprising that the TZ-induced 
cardiotoxicity was almost completely reverted in samples from mice treated with the combination of TZ and 
HFn-DOX, despite the amount of DOX in heart was the same to that measured in HFn-DOX treated mice 
(Supplementary Fig. 2). Also, DOX cardiotoxicity is not surprising and it is clearly attributable to the increased 
accumulation of DOXol. Indeed, this toxic metabolite of DOX is undetectable in samples from mice treated with 
HFn-DOX as single agent or in combination with TZ, but it has been revealed in heart tissue homogenates of 
DOX and DOX + TZ treatment’s groups. Other signs of off-target toxicity were not detected as demonstrated by 
histopathological examination of off- target organs and by functional liver and kidneys functional enzymatic 
assays (Supplementary Fig. 3 and Supplementary Tables 1 and 2).
Figure 2.  Analysis of HFn-DOX and TZ mitochondrial cardiotoxicity. Hearts from treated mice were fixed 
with glutaraldehyde and embedded in epoxy-resin. At least 10 TEM images of ultrathin heart sections have been 
acquired at 4,200 and 11,500 magnifications for each experimental group. Quantification of mitochondria area 
and area occupied by cristae were performed on at least 10 images/group, measuring at least 100 mitochondria/
sample, while count of mitochondria number were performed on at least 10 images/group. Values represent 
the mean mitochondria number ± s.e. (A), the mean mitochondrial area ± s.e. (B) and the percentage of 
mitochondrial area occupied by cristae ± s.e. (C). Statistical significance vs. Placebo ****P < 0.0001; vs TZ 
####P < 0.0001 (Kruskal-Wallis test). (D) Representative images of mitochondria from hearts excised at day 24 
(n = 3/group) from treated mice acquired at 11,500 magnifications evidenced mitochondria morphological 
alterations.
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HFn-DOX coadministration reduces TZ accumulation in heart and improves its tumor penetra‑
tion. To better investigate the rationale of this unexpected results, we tried to quantify the amount of TZ in 
heart lysates by western blot. Results reported in Fig. 3A,B and Supplementary Fig. 6 evidenced that TZ was 
significantly higher in heart from mice treated with TZ alone, despite the TZ dosage was the same administered 
in group treated with DOX + TZ and HFn-DOX + TZ. This result suggests that the co-treatments with HFn-
DOX or DOX alter the TZ biodistribution and off-targeting accumulation. One possible explanation is that the 
killing of cancer cells resulting from HFn-DOX or DOX treatment, is able to modify TZ penetration in cancer. 
To assess this hypothesis, we quantified the amount of TZ in tumor lysates by western blot. Results reported 
in Fig.  3C,D and Supplementary Fig.  7 clearly evidenced that TZ was higher in samples from mice treated 
with HFn-DOX + TZ or DOX + TZ, while it was very low in samples from mice treated only with TZ. This first 
evidence strongly supports our hypothesis, revealing that more TZ reached the tumor, less TZ accumulated in 
off-target organs. To finally assess if the higher accumulation in cancer was really due to improved TZ penetra-
tion, we performed a study of TZ localization. We obtained confocal microscopy images of the whole tumor 
section by mosaic acquisition, as reported in Fig. 3E. Image analysis of reconstituted tumor section confirmed 
the improvement in TZ tumor penetration following the combined treatment with HFn-DOX or DOX, evidenc-
ing the multiple positive effects due to a drug formulation with better targeted delivery (Fig. 3F). To evaluate 
the hypothesis that the better drug penetration of TZ is due to the HFn-DOX or DOX effect against tumor 
stroma, we assessed the amount of Cancer Associated Fibroblasts (CAF) in tumor tissue evaluating the expres-
sion of α-Smooth Muscle Actin (α-SMA). Indeed, CAFs have the major role to create a barrier that prevent drug 
penetration in  tumor17. The analysis of α-SMA fluorescence signal in tumor cryosections evidenced that drug 
treatments reduced α-SMA expression, suggesting a negative effect on CAF for both single treatments and the 
combination (Fig. 3G,H). However, α-SMA biomarker is expressed also in tumor vessel and its reduced expres-
sion could also be ascribed to an alteration of tumor angiogenesis due to different treatments. To elucidate this 
point, immunohistochemistry of CD31 antigen was performed (Supplementary Fig. 4) demonstrating that the 
amount of vessels in tumor tissue was not significantly affected by treatments. Therefore, the decrease in α-SMA 
expression observed in tumor cryosections from treated mice is ascribable to CAF reduction. Moreover, the 
effect observed in mice treated with the TZ and HFn-DOX combination is the highest, despite DOX + TZ, TZ, 
DOX and HFn-DOX employed as single agents already decreased α-SMA labelling in comparison to samples 
from placebo group.
Discussion
The need to reduce DOX and TZ cardiotoxicity in  HER2+ BC patients explains the reason of their sequential 
 administration18. However, it results in elongation of treatment time and potentially in reduction of efficacy 
compared to concurrent administration. In the neoadjuvant setting, concurrent administration of DOX and TZ, 
not only would probably allow a higher pCR  rate19, but it also would let to immediately assess response to NACT. 
In the present study, the concurrent administration of anthracyclines and TZ was allowed by the exploitation of 
a DOX nanoformulation with proved  cardiosafety9. HFn-DOX has been widely studied for the nanometronomic 
treatment of highly aggressive BC, displaying good anticancer activity and poor off-target accumulation with 
fast liver metabolism and rapid  clearance9. This DOX nanoformulation exploits the tumor targeting specificity 
of HFn nanocage, as a result of the specific binding between HFn and the transferrin receptor 1 (TfR1), which 
is overexpressed in  cancers9,20. Moreover, HFn-DOX takes also advantage from its self-triggered mechanism of 
DOX release in the nucleus, that is a consequence of its natural nuclear  homing20. On one hand, the nanovector’s 
features allow to improve DOX anticancer activity, since the tumor targeting specificity and nuclear homing of 
HFn have been demonstrated to give a crucial contribution in improve HFn-DOX antitumor activity. On the 
other hand, they play a role in limit accumulation in off-target organs and hence  cardiotoxicity9. The heart is a 
preferential site of toxicity for BC therapies, since TZ recognizes the HER3 receptor expressed on cardiomyocites 
and affects their pro-survival  pathway21, while anthracyclines, through inhibition of topoisomerase 2β, activate 
cell death pathways and inhibition of mitochondrial  biogenesis21. Therefore, correctly addressing the relevant 
cytotoxic capability of DOX into cancer cells by a properly designed drug delivery system would answer to a 
clinical unmet need. The present study showed that the main consequence of HFn-DOX active targeting toward 
BC cells results in the lacking of  cardiotoxicity9. In this scenario, the safe profile exhibited by HFn-DOX treat-
ment, even after concurrent administration of TZ, represents a promising result.
As demonstrated in Fig. 3, the reason of this result is attributable to variations of systemic drug accumula-
tion in target and off-target organs upon different therapeutic treatments. Surprisingly, the lower cardiotoxicity 
of concurrent administration of TZ and HFn-DOX is not only related to the lower internalization of DOX into 
cardiomiocytes, but also to lower accumulation of  TZ22. Indeed, the TZ quantification in heart homogenates 
evidenced that the absence of cardiotoxic alterations observed in morphological analysis of cardiac mitochon-
dria is coupled with a low accumulation of TZ in cardiac tissue from mice co-treated with TZ and HFn-DOX. 
A possible explanation for this unexpected result might be suggested by the role of CAF in drug delivery and 
interaction with cancer cells. Indeed, the concurrent administration of TZ and HFn-DOX demonstrated the 
highest cytotoxic effect on CAF, assessed by expression of α-SMA. Lacking the protective role of CAF toward 
cancer cells, a greater penetration of TZ was noted in tumor cells when HFn-DOX was co-administered, despite 
the same amount of TZ was used in experimental groups. Therefore, lower accumulation of TZ was found in heart 
homogenates, further explaining the reduction of cardiotoxicity. This increased penetration seems to be due to a 
cytotoxic effect on CAFs. Indeed, confocal microscopy imaging performed to enumerate CAFs in tumors upon 
different treatment evidenced that both TZ accumulation and drugs anticancer efficacy is inversely related to 
CAFs amount in tumor, suggesting that HFn-DOX treatment modifies tumor microenvironment (TME), with 
important consequences both in treatment’s efficacy, both in toxicity.
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In other words, by modulating the action of DOX toward BC cells and TME thanks to nanoformulation, TZ 
is also easily addressed at tumor sites, lowering accumulation in off-target organs. Beyond the fact that TME acts 
as a barrier to prevent drug penetration, also immune-modulating effects of TME might be affected by HFn-
DOX, reducing the inhibition of cytotoxic T cells and natural killer T cells by CAF and enhancing the action of 
immune-related treatments such as  TZ23.
A cardiosafe anthracycline is still a mirage for oncologists. Several formulations of anthracyclines have been 
tested, including epirubicin, but none of them has demonstrated a significant reduction of heart damage com-
pared to  DOX24. A point of controversy is that clinically relevant heart failure is relatively infrequent, accounting 
for about 5% of patients treated with a cumulative dose of anthracyclines equal to 400 mg/m225. But it represents 
only the “tip of the iceberg” of cardiotoxicity, since accounting also for asymptomatic left ventricular dysfunc-
tion, 18% of patients show cardiotoxicity after a cumulative dose of 350 mg/m2, and 65% after a total dose of 
550 mg/m225. Actually it is not clear which proportion of patients with asymptomatic ventricular dysfunction 
will develop clinically relevant heart failure, but the magnitude of this therapeutic concern is  real26,27. Clinical 
translation of concurrent therapy with TZ and HFn-DOX might address this major issue.
Methods
HFn-DOX production. HFn nanocages were produced and purified as previously  reported20 DOX load-
ing procedure has been performed using the pH-dependent disassembling/reassembling procedure already 
 reported20 and characterized by absorbance, fluorescence and dynamic light scattering analysis.
cell cultures. D2F2/E2 cell line was used to establish the murine model of orthotopic HER2 positive-BC 
cells. It stably expresses human HER2 receptor and has been obtained by Prof. Wei Zen-Wei (Wayne University) 
in 2016 from by MTA. D2F2/E2 cells were cultured in DMEM high glucose containing Sodium Pyruvate (1%), 
fetal bovine serum (10%), MEM non-essential aminoacids (1%), L-glutamine (2 mM), penicillin (50 UI  mL−1), 
streptomycin (50 mg mL−1) and G418 (0.8 mg mL−1) at temperature of 37 °C, in 5%  CO2. Cells were passaged 
using trypsin/EDTA and amplified for 2–4 weeks, before tumor implant. All cell culture reagents were purchased 
by Euroclone (Italy).
Production of orthotopic tumor model. BALB/c mice (female, 8-week old) provided by Charles River 
Laboratories (Calco, Italy), were maintained in the animal facility, housed in single cages without food limitation 
and monitored  daily9. Anestesia has been performed by inhalation of 2.5% isofluorane. Animals were handled 
in accordance with an experimental protocol approved by the Italian Ministry of Health. Sixty BALB/c mice 
were subjected to abdominal trichotomy two day before the injection of tumor cells. D2F2/E2 cells (1 × 106 cells 
/animal) were suspended in cold serum-free DMEM high glucose medium and ortotopically injected into mam-
mary gland. Mice wellness were monitored daily, and tumors were measured every two days. About 5 days after 
the implant, a small primary nodule (about 0.3 cm × 0.3 cm) is visible.
Study design. The hypothesis to test was that DOX nanoformulation in H-Ferritin nanocages would allow 
its contemporary administration with TZ exhibiting higher antitumor efficacy without displaying cardiotoxicity. 
HFn-DOX or DOX were administered intravenously (i.v.) in tail vein at the DOX dosage of 1 mg kg−1, which 
is about 1/10 of the average amount of DOX administered in Dose-Dense  regimen28, while TZ was intraperito-
neally (i.p.) injected at the dosage of 5 mg kg−1. Six groups of treatment were performed (N = 15 mice/group): 
placebo, HFn-DOX alone, DOX alone, TZ alone, HFn-DOX + TZ and DOX + TZ. Mice have been treated 5 
times, with twice treatments a week. The number of animals for each experimental group was calculated with 
a statistical power of at least 80 ± 5%. The experimental endpoint was set up at 24 days after cells injection to 
assess in vivo antitumor activity and cardiotoxicity due to different treatments. This time point was chosen to 
work in compliance with the European and Italian laws about welfare of research animal and in the meantime to 
discriminate differences in antitumor efficacy and/or cardiotoxicity due to different treatments. Before starting 
treatments, mice were randomly divided in experimental groups by primary tumor size. Rodents were moni-
Figure 3.  TZ quantification in heart and tumor tissue. Western blot analysis of hearts (panels A and B) and 
tumor (panels C and D) excised at the end of treatment to quantify TZ. (A,C) Representative results of western 
blots performed to quantify TZ, constituted by cropped western blots revealed with anti-human IgG HRP 
antibody and anti-GAPDH, respectively. (B,D) TZ quantification in heart and tumor, respectively. TZ was 
normalized on GAPDH using ImageJ Software. Reported values are the mean of 3 samples ± s.e. Statistical 
significance vs. TZ, *P < 0.05, **P < 0.01, ***p < 0.005. (E) Representative images of confocal microscopy analysis 
of TZ penetration in tumor from mice treated with placebo,TZ alone or in combination with HFn-DOX or 
DOX. DAPI signal is white, while TZ is labelled in red. Scale bar = 500 μm. (F) Analysis of spatial distribution 
of TZ fluorescence signal. Quantification of mean fluorescence intensity (MFI) of anti-Trastuzumab staining 
along the tumor axis from the edge to the geometric center (mean ± s.e [s.e. bars in grey color]; n = 3 tumor 
mosaics/staining; statistical comparisons between measurement points are shown). The black line represents the 
calculated average background of stained tumor cryosections from mice treated without trastuzumab (n = 3). 
Statistical significance vs. TZ, *P < 0.05, **P < 0.01. (G) Representative images of α-SMA labelling in frozen 
cryosections of tumors from treated mice (n = 3/group) to assess the amount of Cancer Associated Fibrolasts 
(CAF). (H) Quantification of the fluorescence signal of α-SMA labelling. Reported values are the mean of 3 
samples ± s.e. Statistical significance vs. placebo ##P < 0.01, ###P < 0.005; vs DOX *P < 0.05.
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tored measuring tumor size progression in blind by the same operator using the caliper. Tumor volume has been 
determined using the following equation: Tumor volume  (mm3) = lenght × (width)2/2.
Resected tissues from animals euthanized at day 24 were analyzed to evaluate the effects of different treatments 
on tumor growth, tumor angiogenesis and also cardiotoxicity, without excluding outliers. Histopathology and 
immunohistochemistry were performed in blind.
Ex-vivo analysis of tumor cryosections. Tumors (n = 8/group) resected at day 24, were sectioned into 
two similar parts. One has been processed for cryosectioning, and the other has been treated for paraffin embed-
ding. After a fixation step of 3 h in 4% paraformaldehyde, samples have been washed, embedded in OCT and 
freezed in liquid nitrogen before cryosectioning. Tumor cryosections (9 µm thick) were thawed at room tem-
perature for 15 min, washed with PBS and labelled with Alexa Fluor 488 wheat germ agglutinin (when neces-
sary). Then, after a permeabilization step of 5 min at room temperature (RT) in PBS supplemented withTriton 
X-100 (0.1%), a blocking step of 1 h as been performed at RT in PBS supplemented with BSA (2%) and goat 
serum (2%), followed by the labelling with primary antibodies for 2 h at RT. α-SMA antibody (1:400 in block-
ing buffer; Cell Signalling Technology #19245), Alexa Fluor 488 anti-human IgG antibody (1:400 dilution in 
blocking buffer; Life Technology #A-11013) or cleaved caspase 3 antibody (1:300 diluition in blocking buffer; 
Cell signaling Technology D175 #9661) have been respectively used to detect CAF, TZ or apoptosis. α-SMA 
and anti- cleaved caspase 3 labelled samples were labelled for 2 h at RT with goat Alexa Fluor-546 anti-rabbit 
secondary antibody (1:400 in blocking buffer; life technology #A-11010) after PBS washing. At the end of the 
immunocytochemistry reactions, samples were counterstained with DAPI (10 µM, 10 min at RT), washed thrice 
and mounted with Prolong Gold (Life technology; #P10144). Images of tumor cryosections were acquired at 
40 × magnification with a Leica SP8 microscope confocal system using laser excitation lines 405 nm, 488 nm, 
535 nm. Resolution of images is of 1,024 × 1,024 or 512 × 512 pixel.
Immunohistochemistry. Resected D2F2/E2 tumors formalin-fixed and paraffin embedded were sec-
tioned into Three micrometer thick slices (n = 5/group). Samples were processed for CD31 immunohistochem-
istry as previously  described9. The number of vessels was counted on 10 fields/sample, field size 1 mm × 1 mm.
Apoptosis assay. Paraffin-embedded tumor sections (n = 8/group; Three micrometer thick) were processed 
with the Tumor TACS In Situ Apoptosis Detection kit (Trevigen)9 or with Click-iT TUNEL Colorimetric ICH 
Detection kit (Invitrogen) according to manufacturer’s protocols. Apoptotic nuclei labeled by diaminobenzidine 
were counted on 10 squares/sample (n = 8/group). Magnification 20 × .
Flow cytometry. D2F2/E2 tumors surgically removed from treated mice (n = 4/group) were isolated at day 
24 and dissociated in single cell suspension by tumor dissociation kit (Miltenyi # 130-096-730) and gentleMACS 
dissociator (Miltenyi # 130-093-235) following the manufacturer’s instructions. A staining of single cell suspen-
sion has been performed with anti-CD45 (clone 30F11, Miltenyi), anti-CD3 (clone REA641, Miltenyi) and anti-
CD49b (clone DX5, Miltenyi) antibodies. Data were collected on an Gallios cytometer (Beckman Coulter) and 
analysed with FlowJo software (TreeStar).
Histopathological analysis. Liver, kidneys, spleen, heart, brain, gut and lung samples obtained from 
Balb/C mice (n = 3/group) were fixed in 10% buffered formalin for at least 48 h and embedded in  paraffin9. Three 
micrometer sections were cut, stained with hematoxylin and eosin, and examined in a blinded  manner9.
Ultrastructural analysis (TEM). From 4 mice/group, a portion of heart tissue excised during the sacrifice 
has been fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer, pH 7.2, for 2 h. After one rinsing with PBS, 
specimens were post-fixed in 1.5% osmium tetroxide for 2 h, dehydrated by 50, 70, 90, and 100% EtOH, and 
embedded in epoxy resin (PolyBed 812 Polysciences Inc.). Ultrathin sections were cut with an ultramicrotome 
(Ultracut E (Reichert-Jung)), stained with uranyl acetate and lead citrate and examined by TEM (Tecnai Spirit, 
FEI)9. For mitochondria quantification at least 10 images/group were taken at 4,200 × magnification9. Four mice 
were used for each experimental condition. Mitochondrial morphometric measurements were performed using 
ImageJ software on at least 10 images/group acquired at 11.500 × magnification measuring the area of at least 
100 mitochondria/sample9. The percentage of area occupied by mitochondrial cristae was measured by ImageJ 
software imposing a threshold value of  1189.
Assessment of kidney and liver functionality. Kidney and liver functionality were assessed as previ-
ously described (n = 6/group), using the following kits: QuantiChromTM Urea Assay Kit, QuantiChromTM Cre-
atinine Assay Kit, EnzyChromTM Aspartate Transaminase Assay Kit and EnzyChromTM Alanine Transaminase 
Assay Kit (BioAssay Systems)9.
Doxorubicin quantification in heart. Heart from treated mice (n = 3–4/group) were processed and 
quantified by a liquid chromatography tandem mass spectrometry as previously  reported29. The heart tissue 
matrix was added to the published method. Sensitivity, specificity, precision, accuracy, recovery and matrix 
effect of extraction and quantification procedures have been assessed in compliance to the US Food and Drug 
Administration (FDA) guidelines for bioanalytical methods’ validation. Quantification were performed using 
Daunorubicine and Doxorubicinol as internal standards on standard curve prepared in heart homogenates . The 
data are the mean ± SE of samples collected from at least 3 different mice.
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Western blot. D2F2/E2 tumors and hearts from treated mice (n = 3/group) were isolated at day 24 and 
homogenized in water (10% w/v)29. After a lysis step of 30 min at 4 °C in 20 mM Tris HCl pH 7.6, 150 mM 
NaCl, 1 mM EDTA, 1% Triton X-100, 1% glycerol, 1 mM  Na3VO4, 10 mM NaF, Protease Inhibitor Cocktail, 
1 mM PMSF, samples were centrifuged (6,000 × g for 10 min at 4 °C) to discard cell debris. Protein content was 
determined by Bradford assay, BSA has been used to obtain a standard curve. For evaluation of Granzyme B, 
approximately 30 µg of lysate was loaded on SDS-PAGE (10% acrylamide) and blotted onto PVDF membrane. 
After a blocking step of 1 h at RT in blocking buffer (TBS supplemented with nonfat dry milk (5%) and Tween 
20 (0.1%)), membrane was labelled with anti-Granzyme B antibody (Cell Signalling Technlogy #4275; 1:1,000 
in blocking buffer) at 4 °C overnight. Then, a washing step was performed using TBS supplemented with 0.1% 
Tween 20 and repeated twice, before 1 h at RT incubation with goat Anti-rabbit-HRP secondary antibody in 
blocking buffer (Abcam, #ab97200; dilution 1:4,000). Finally, the washing step was performed thrice. To evaluate 
TZ accumulation, approximately 35 µg of protein from each sample were loaded on SDS-PAGE (12% acryla-
mide). Then, proteins were transferred to the membrane (PVDF; Sigma-Aldrich) and blocked in in blocking 
buffer (TBS supplemented with nonfat dry milk (5%) and Tween 20 (0.1%))for 1 h. TZ was labelled by overnight 
incubation at 4 °C with goat anti-human monoclonal antibody conjugated with horseradish peroxidase (Tebu-
bio, #GTX26759) at 1:2000 dilution in washing buffer (TBS with 0.1% Tween 20). After a washing step repeated 
thrice, the ECL star reagent (Euroclone) was used for chemioluminescence emission, which is capture by the 
Chemidoc System (Biorad).
Statistical analysis. T-test, one-way ANOVA or Kruskal-Wallis tests performing multiple comparison 
have been used for statistical analysis, assuming normal distribution. P-values < 0.05 were considered as statisti-
cal significant.
Ethics statements. Investigation has been performed according to national and international guidelines 
and to Declaration of Helsinki. Moreover, it has been approved by the institutional review board of the Univer-
sity of Milan. A protocol about activity on animals has been approved by the Italian Ministry of Health (Authori-
zation number 520/2017-PR).
Data availablility
Raw data will be available upon request at the following URL https ://doi.org/10.13130 /RD_UNIMI /I4YV9 7.
Received: 25 February 2019; Accepted: 22 June 2020
References
 1. Buzdar, A. U. et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, 
and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2–positive operable breast 
cancer. JCO 23, 3676–3685 (2005).
 2. Cortazar, P. et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. 
Lancet 384, 164–172 (2014).
 3. Untch, M. et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in 
human epidermal growth factor receptor 2–overexpressing breast cancer: Results from the techno trial of the AGO and GBG study 
groups. JCO 29, 3351–3357 (2011).
 4. Hudis, C. A. Trastuzumab—mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39–51 (2007).
 5. Gianni, L. et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): 
Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 15, 640–647 (2014).
 6. Vogel, C. L. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic 
breast cancer. JCO 20, 719–726 (2002).
 7. Wadhwa, D. et al. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: A retrospective 
study. Breast Cancer Res. Treat. 117, 357–364 (2009).
 8. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses 
HER2. N. Engl. J. Med. 344, 783–792 (2001).
 9. Mazzucchelli, S. et al. Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and 
circumvents cardiotoxicity. Oncotarget 8, 8383–8396 (2017).
 10. Clynes, R. A., Towers, T. L., Presta, L. G. & Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. 
Nat Med 6, 443–446 (2000).
 11. Azim, H., Azim, H. A. & Escudier, B. Trastuzumab versus lapatinib: The cardiac side of the story. Cancer Treat. Rev. 35, 633–638 
(2009).
 12. Zhang, S. et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18, 1639–1642 (2012).
 13. Ades, F. et al. Cardiotoxicity of systemic agents used in breast cancer. Breast 23, 317–328 (2014).
 14. Baselga, J., Norton, L., Albanell, J., Kim, Y. M. & Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances 
the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer 
Res. 58, 2825–2831 (1998).
 15. Gianni, L. et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast 
cancer: A 4-year follow-up of a randomised controlled trial. Lancet Oncol. 12, 236–244 (2011).
 16. Gianni, L. et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy 
alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial 
with a parallel HER2-negative cohort. Lancet 375, 377–384 (2010).
 17. Logsdon, D. K., Beeghly, G. F. & Munson, J. M. Chemoprotection across the tumor border: Cancer cell response to doxorubicin 
depends on stromal fibroblast ratios and interstitial therapeutic transport. Cell Mol. Bioeng. 10, 463–481 (2017).
 18. Kim, J. et al. Association between FDG uptake in the right ventricular myocardium and cancer therapy-induced cardiotoxicity. J 
Nucl Cardiol 2, 1 (2019).
10
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:11425  | https://doi.org/10.1038/s41598-020-68205-w
www.nature.com/scientificreports/
 19. Antolín, S. et al. Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: Efficacy 
data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution. Breast Cancer 
(Dove Med Press) 11, 29–42 (2019).
 20. Bellini, M. et al. Protein nanocages for self-triggered nuclear delivery of DNA-targeted chemotherapeutics in Cancer Cells. J. 
Control Release 196, 184–196 (2014).
 21. Nemeth, B. T., Varga, Z. V., Wu, W. J. & Pacher, P. Trastuzumab cardiotoxicity: From clinical trials to experimental studies. Br. J. 
Pharmacol. 174, 3727–3748 (2017).
 22. Henriksen, P. A. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart 104, 971–977 (2018).
 23. Mittal, S., Brown, N. J. & Holen, I. The breast tumor microenvironment: Role in cancer development, progression and response 
to therapy. Expert Rev. Mol. Diagn. 18, 227–243 (2018).
 24. van Dalen, E. C., Michiels, E. M., Caron, H. N. & Kremer, L. C. Different anthracycline derivates for reducing cardiotoxicity in 
cancer patients. Cochrane Database Syst. Rev. 6, 5006 (2010).
 25. Swain, S. M., Whaley, F. S. & Ewer, M. S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of 
three trials. Cancer 97, 2869–2879 (2003).
 26. Cardinale, D., Colombo, A. & Cipolla, C. M. Treating asymptomatic chemotherapy-induced cardiac dysfunction: A chance that 
cardiologists and oncologists should not miss. J. Am. Coll. Cardiol. 57, 1790 (2011).
 27. Chang, H.-M., Okwuosa, T. M., Scarabelli, T., Moudgil, R. & Yeh, E. T. H. Cardiovascular complications of cancer therapy: Best 
practices in diagnosis, prevention, and management: Part 2. J. Am. Coll. Cardiol. 70, 2552–2565 (2017).
 28. Zhang, L. et al. H-chain ferritin: A natural nuclei targeting and bioactive delivery nanovector. Adv. Healthcare Mater. 4, 1305–1310 
(2015).
 29. Mazzucchelli, S. et al. LC-MS/MS method development for quantification of doxorubicin and its metabolite 13-hydroxy doxoru-
bicin in mice biological matrices: Application to a pharmaco-delivery study. Biomed. Chromatogr. 31, 2 (2017).
Acknowledgements
We thank Dr. E. Tagliabue and T. Triulzi for helpful discussion and Prof. W. Zen-Wei for D2F2/E2 for cell line. 
We acknowledge the Pediatric Clinical Research Center “Romeo and Enrica Invernizzi” at University of Milan 
for imaging facility and for SM support. The research was supported by the Regione Lombardia and Fondazione 
Cariplo (2016-0919 to S. M.). UNIMI supported MT with Research Fellowship.
Author contributions
S.M. and F.C. conceived and design the study. M.B. and D.P. produced void HFn. R.O. and S.C. quantified DOX. 
E.L. and B.M. performed ICH, tunel assay and E&E staining. R.A. performed TEM samples preparation and 
images acquisition. S.M., F.A., A.B., M.M., L.S., M.S., L.S., F.S. and M.T. performed in vivo experiment, tissue 
post-processing, immunofluoresce stainings, western blot and flow cytometry. S.M., P.Z., C.M., R.V. and F.A. 
analyzed the data. S.M. and F.C. wrote the manuscript.
competing interests 
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https ://doi.org/10.1038/s4159 8-020-68205 -w.
Correspondence and requests for materials should be addressed to F.C. or S.M.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this license, visit http://creat iveco mmons .org/licen ses/by/4.0/.
© The Author(s) 2020
